Those aiming for above-average market returns often engage in the meticulous process of stock picking. Choosing the right stocks can make a substantial difference in your wealth.
After finishing at $8.75 in the prior trading day, AdaptHealth Corp (NASDAQ: AHCO) closed at $8.86, up 1.26%. In other words, the price has increased by $1.26 from its previous closing price. On the day, 0.96 million shares were traded.
Ratios:
Our goal is to gain a better understanding of AHCO by taking a closer look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 22.29 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 4.35. For the most recent quarter (mrq), Quick Ratio is recorded 1.07 and its Current Ratio is at 1.29. In the meantime, Its Debt-to-Equity ratio is 1.34 whereas as Long-Term Debt/Eq ratio is at 1.30.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Jefferies on January 08, 2024, Downgraded its rating to Hold and sets its target price to $8 from $14.50 previously.
On November 08, 2023, BofA Securities Downgraded its rating to Underperform which previously was Neutral and also lowered its target price recommendation from $9.50 to $6.50.
Stifel Downgraded its Buy to Hold on May 10, 2023, whereas the target price for the stock was revised from $18 to $11.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Dec 19 ’24 when Rietkerk Shaw bought 32,500 shares for $9.70 per share.
Clemens Jason A sold 35,000 shares of AHCO for $327,250 on Dec 10 ’24. The Chief Financial Officer now owns 420,719 shares after completing the transaction at $9.35 per share. On Dec 10 ’24, another insider, JASON A CLEMENS &BIANCA S VITA, who serves as the Officer of the company, bought 35,000 shares for $9.35 each.
Valuation Measures:
As of this moment, AdaptHealth’s Price-to-Earnings (P/E) ratio for their current fiscal year is 15.62, and their Forward P/E ratio for the next fiscal year is 7.38. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 2.40. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.37 while its Price-to-Book (P/B) ratio in mrq is 0.75.
Stock Price History:
Over the past 52 weeks, AHCO has reached a high of $11.90, while it has fallen to a 52-week low of $7.11. The 50-Day Moving Average of the stock is -1.82%, while the 200-Day Moving Average is calculated to be -10.81%.
Shares Statistics:
A total of 132.01M shares are outstanding, with a floating share count of 86.66M. Insiders hold about 35.79% of the company’s shares, while institutions hold 74.81% stake in the company.
Earnings Estimates
A comprehensive evaluation of AdaptHealth Corp (AHCO) is underway, with the input of 6.0 analysts contributing to its current rating.The consensus estimate for the next quarter is $0.34, with high estimates of $0.4 and low estimates of $0.27.
Analysts are recommending an EPS of between $1.14 and $0.95 for the fiscal current year, implying an average EPS of $1.04. EPS for the following year is $1.21, with 6.0 analysts recommending between $1.38 and $0.99.
Revenue Estimates
8 analysts predict $804.97M in revenue for the current quarter. It ranges from a high estimate of $807.68M to a low estimate of $802.4M. As of the current estimate, AdaptHealth Corp’s year-ago sales were $805.98MFor the next quarter, 8 analysts are estimating revenue of $809.31M. There is a high estimate of $818.3M for the next quarter, whereas the lowest estimate is $803.5M.
A total of 8 analysts have provided revenue estimates for AHCO’s current fiscal year. The highest revenue estimate was $3.26B, while the lowest revenue estimate was $3.24B, resulting in an average revenue estimate of $3.25B. In the same quarter a year ago, actual revenue was $3.26BBased on 8 analysts’ estimates, the company’s revenue will be $3.4B in the next fiscal year. The high estimate is $3.49B and the low estimate is $3.34B.
